HFGB was already the leading supplier of "rutin" in China & has been filling huge order increases for that product & "diosmin" from new & expanded contracts from Europe.
This acquisition is not only acretive to eps but adds needed manufactoring capacity at a time it is trying to fill its backlog.
Since cashflow & pps is not high enough presently to complete HFGB's mission of becoming a much bigger full pharm.
The company is doing a good job of getting the best results from the present situation.
Smart management is adapting to reasonable & affordable ways to grow the company.[notice the shares were not only accepted @$0.70 when the current pps was $0.55 but they are restricted from trading those shares for 1 year.]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.